Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.39 USD | -3.96% | -9.82% | -32.61% |
Apr. 20 | Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing | MT |
Apr. 20 | Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing | MT |
Business Summary
Number of employees: 164
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 19-05-31 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 21-10-03 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ian Gourley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Maria Alba
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jennifer Moseley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-08-23 |
Jay Stout
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-03-31 |
Chief Tech/Sci/R&D Officer | 66 | 21-05-31 | |
Chau Cheng
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 19-12-17 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 19-12-17 |
Douglas Hughes
BRD | Director/Board Member | 62 | 19-12-17 |
Atul Pande
BRD | Director/Board Member | 69 | 19-12-17 |
Frank Torti
CHM | Chairman | 45 | 19-12-17 |
Eric Venker
BRD | Director/Board Member | 37 | 20-02-17 |
Peter Salzmann
CEO | Chief Executive Officer | 56 | 19-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 145,292,970 | 61,654,201 ( 42.43 %) | 0 | 42.43 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.61% | 4.29B | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- IMVT Stock
- Company Immunovant, Inc.